MaiaMilk is a shelf-stable, powdered human donor milk product designed to bring medical-grade infant nutrition out of hospital NICUs and straight to families at home. Unlike formula, MaiaMilk isn't reeingineered or a replication of breast milk, it's 100% human milk that has been freeze-dried and conveniently packaged for moms. Thanks to proprietary technology, the product preserves breast milk’s bioactive compounds, antibodies, and nutrients, and still makes the portable, convenient formula made without synthetic additives, fortifiers and preservatives, ready to prepare with water.
"We’ve seen how essential donor milk is for the most vulnerable infants," said Tara Overton, Head of Operations for MaiaMilk. "But we’ve also seen the limitations of a system where access is confined to hospitals. Making donor milk shelf-stable and standardized wasn’t just a technical challenge, it was a responsibility."
Freeze-Dried Breast Milk Powders
MaiaMilk is the World's First Powdered Donor Breast Milk
Trend Themes
1. Shelf-stable Human Milk - A growing market for shelf-stable powdered human milk that preserves bioactive compounds and antibodies, supporting decentralized supply and extended distribution lifecycles.
2. Preservation of Bioactives - Advances in freeze-drying and stabilization that retain antibodies, enzymes, and nutrients, opening pathways for clinically validated preserved biological products.
3. Humanized Formula Alternatives - Rising parental preference for human-derived, additive-free infant nutrition positioning donor milk powders as premium substitutes to synthetic formulas.
Industry Implications
1. Infant Nutrition - The infant nutrition industry experiencing new product categories centered on authentic human milk powders with implications for formulation, labeling, and clinical validation.
2. Cold-chain Logistics - Logistics and supply-chain operations shifting from refrigerated models toward ambient-stable distribution that can lower costs and expand last-mile access.
3. Biotech and Therapeutics - Biotech companies leveraging preservation and stabilization techniques to adapt biologics delivery platforms and develop immune-supporting or neonatal-focused therapies.